Polymorphisms and gene expression of metalloproteinases and their inhibitors associated with cerebral ischemic stroke in young patients with sickle cell anemia
Authors:
- Ó. Do Kleyton PalmeiraÓPÓ. Do Kleyton Palmeira
- Ana Karla da Silva FreireAFAna Karla da Silva Freire
- Débora Nascimento de NóbregaDNDébora Nascimento de Nóbrega
- Roberta dos Santos SouzaRSRoberta dos Santos Souza
- Isabela Cristina Cordeiro FariasIFIsabela Cristina Cordeiro Farias
- Taciana Furtado de Mendonça BelmontTBTaciana Furtado de Mendonça Belmont
- Andreia Soares da SilvaASAndreia Soares da Silva
- Gabriela da Silva ArcanjoGAGabriela da Silva Arcanjo
- Aderson da Silva AraujoAAAderson da Silva Araujo
- Ana Cláudia Mendonça dos AnjosAAAna Cláudia Mendonça dos Anjos
- Antônio Roberto Lucena de AraujoAAAntônio Roberto Lucena de Araujo
- Marcos André Cavalcanti BezerraMBMarcos André Cavalcanti Bezerra
- 1 February 2023
- journal article
- research article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (4) , 3341-3353
Abstract
Background Sickle cell anemia (SCA) is a genetic disease with great clinical heterogeneity and few viable strategies for treatment; hydroxyurea (HU) is the only widely used drug. Thus, the study of single nucleotide polymorphisms (SNPs) and the gene expression of MMPs 1, 2, 9, 7 and TIMPs 1 and 2, which are involved in the regulation of extracellular matrix, inflammation, and neuropathies, may provide further insights into the pathophysiology of the disease and elucidate biomarkers and molecules as potential therapeutic targets for patients with SCA. Methods and results We evaluated 251 young individuals with SCA from northeastern Brazil. The groups were divided according to vaso-occlusive crisis (VOC) and cerebrovascular disease (CVD), compared to control individuals. SNP detection and gene expression assays were performed by real-time PCR, TaqMan system®. Both the expression levels of MMP1 gene, and the SNP MMP1-1607 1G/2G were associated with the risk of cerebral ischemic stroke (IS), and the expression of MMP1 was also associated with a higher frequency of VOC/year. Expression levels of MMP7, TIMP1, and TIMP2 were increased in patients conditioned to IS. The SNP 372T>C (rs4898) TIMP1 T alleles were more frequent in patients with > 5 VOC events/year. The SNP rs17576 of MMP9 showed differences in gene expression levels; it was increased in the genotypes AG, and AG+GG. Conclusion The findings of this study, the SNPs, and expression provide initial support for understanding the role of MMPs-TIMPs in the pathophysiology of SCA in young patients.Keywords
All Related Versions
Funding Information
- CAPES (Code 001)
This publication has 47 references indexed in Scilit:
- TIMP-1 Attenuates Blood–Brain Barrier Permeability in Mice with Acute Liver FailureJournal of Cerebral Blood Flow & Metabolism, 2013
- Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic StrokeFrontiers in Neurology, 2013
- MMP1 bimodal expression and differential response to inflammatory mediators is linked to promoter polymorphismsBMC Genomics, 2011
- Increased Plasma and Tissue MMP Levels are Associated with BCSFB and BBB Disruption Evident on Post-Contrast FLAIR after Experimental StrokeJournal of Cerebral Blood Flow & Metabolism, 2010
- Implications of Vascular Endothelial Growth Factor for Postischemic Neurovascular RemodelingJournal of Cerebral Blood Flow & Metabolism, 2009
- Genetic complexity in sickle cell diseaseProceedings of the National Academy of Sciences, 2008
- Fisiopatologia das doenças falciformes: da mutação genética à insuficiência de múltiplos órgãosRevista Brasileira de Ginecologia e Obstetrícia, 2007
- Role of TIMP-1 and TIMP-2 in the Progression of Cerebral AneurysmsStroke, 2007
- Prevention and Management of Stroke in Sickle Cell AnemiaHematology-American Society Hematology Education Program, 2006
- Dysregulation of the Levels of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinases in the Early Phase of Cerebral IschemiaStroke, 2003